Edge Therapeutics’ EG-1962 Data To Be Presented at International Stroke Conference 2017
February 17 2017 - 7:00AM
Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage
biotechnology company developing novel hospital-based therapies in
the management of acute, life-threatening conditions, today
announced that two posters on Edge’s lead product candidate,
EG-1962, will be presented at the International Stroke Conference
(ISC) 2017 to be held February 22-24, 2017 in Houston, Texas.
EG-1962, is currently being investigated in the pivotal Phase 3
NEWTON 2 (Nimodipine microparticles
to Enhance
recovery While
reducing TOxicity after
subarachNoid hemorrhage) clinical study comparing
the efficacy and safety of EG-1962 administered through an external
ventricular drain (EVD) compared to oral nimodipine in adults who
suffer an aneurysmal subarachnoid hemorrhage (aSAH) resulting from
a ruptured brain aneurysm.
Details of the presentations are as follows:
Title: CTP29 - NEWTON 2: Phase 3, Multicenter,
Randomized, Double-blind, Placebo-controlled, Parallel-group,
Efficacy and Safety Study Comparing EG-1962 to Standard of Care
Oral Nimodipine in Adults with Aneurysmal Subarachnoid
HemorrhageSession: CT P1 - Ongoing Clinical Trials
Posters IIDate / Time: Thursday, February 23, 6:15
- 6:45 p.m. Central TimeLocation: Hall
EPresenter: Daniel Hänggi, M.D., University
Medical Center Mannheim, Ruprecht-Karls-University,
Heidelberg, Germany
Title: TP425 - How do Different Outcome
Measures Reflect Outcome After Aneurysmal Subarachnoid
HemorrhageSession: P35 - SAH and Other
Neurocritical Management Posters IIDate / Time:
Thursday, February 23, 6:15 - 6:45 p.m. Central
TimeLocation: Hall
EPresenter: Daniel Hänggi,
M.D., University Medical Center Mannheim,
Ruprecht-Karls-University, Heidelberg, Germany
For additional information, please visit the ISC website.
About EG-1962
EG-1962 is a novel polymeric nimodipine microparticle containing
nimodipine suspended in a diluent of sodium hyaluronate. EG-1962
utilizes Edge’s proprietary PrecisaTM development platform and
is designed to improve patient outcomes following aSAH. EG-1962 has
been granted Fast Track designation by the U.S. Food and Drug
Administration (FDA), and orphan drug designation by
the FDA and the European Commission.
About Edge Therapeutics, Inc.
Edge Therapeutics, Inc. is a clinical-stage biotechnology
company that discovers, develops and seeks to commercialize novel,
hospital-based therapies capable of transforming treatment
paradigms for the management of acute, life-threatening
neurological and other conditions. EG-1962, Edge’s lead product
candidate, has the potential to fundamentally improve patient
outcomes and transform the management of aneurysmal subarachnoid
hemorrhage, which is bleeding around the brain due to a ruptured
brain aneurysm. Edge is evaluating EG-1962 in two clinical studies:
the pivotal Phase 3 NEWTON 2 study of EG-1962 delivered via
external ventricular drain, and a study of direct intracisternal
administration of EG-1962. For additional information about Edge,
please visit www.edgetherapeutics.com.
Forward-Looking StatementsThis press release
and any statements of representatives of Edge Therapeutics, Inc.
related thereto that are not historical in nature contain, or may
contain, among other things, certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements may include, without
limitation, statements with respect to Edge’s plans, objectives,
projections, expectations and intentions and other statements
identified by words such as "projects," "may," "will," "could,"
"would," "should," "believes," "expects," "anticipates,"
"estimates," “seeks,” "intends," "plans," "potential" or similar
expressions, including statements with respect to Edge’s future
clinical plans, Edge’s ability to advance its portfolio of
therapies towards commercialization and the potential effects of
its products. These statements are based upon the current beliefs
and expectations of Edge’s management and are subject to
significant risks and uncertainties. Actual results may differ
significantly from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks
and uncertainties that are subject to change based on various risk
factors (many of which are beyond Edge's control) as described
under the heading "Risk Factors" in Edge’s filings with the United
States Securities and Exchange Commission.
Investor Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)
Email: ir@edgetherapeutics.com
Media Contact:
Laura Bagby
6 Degrees
Tel: 312-448-8098
Email: lbagby@6degreespr.com
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Apr 2023 to Apr 2024